Evidence map›Paper›PMID 23828106›Full record

Trial reportAJNR. American journal of neuroradiology2013

Reduced mortality and severe disability rates in the SENTIS trial.

P D Schellinger, A Shuaib, M Köhrmann, D S Liebeskind, T Jovin, M D Hammer, S Sen, D Y Huang, S Solander, R Gupta and 3 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in AJNR. American journal of neuroradiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Sex Differences in the Cerebral Collateral Circulation.Translational stroke research · 2017
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 3 countries.

P D SchellingerFrom JW Klinikum, Minden, Germany.
A Shuaib
M Köhrmann
D S Liebeskind
T Jovin
M D Hammer
S Sen
D Y Huang
S Solander
R Gupta
R R Leker
J L Saver
SENTIS Trial Investigators
University of California, Los Angeles · USUniversity of Pittsburgh Medical Center · USEmory University · USJohannes Wesling Klinikum Minden · DESaint Thomas Health · USUniversitätsklinikum Erlangen · DEUniversity of Alberta · CAUniversity of North Carolina at Chapel Hill · USUniversity of South Carolina · US

Funding

UCLA SPOTRIAS CENTER APPLICATION RENEWAL-PROGRAM PROJECTP50NS044378 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VINTERS, HARRY V. · 2003 to 2012
$17.2M
University of Pittsburgh Clinical and Translational Science InstitutionKL2TR000146 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$8.7M
Modeling of Collateral Perfusion in the Ischemic BrainK24NS072272 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIEBESKIND, DAVID SIGMUND · 2011 to 2015
$939k
International Symposium on Collaterals to the BrainR13NS082049 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIEBESKIND, DAVID SIGMUND · 2012 to 2012
$10k
NCATS NIH HHS KL2 TR000146NINDS NIH HHS K24 NS072272NINDS NIH HHS K24NS072272NINDS NIH HHS P50 NS044378NINDS NIH HHS P50NS044378NINDS NIH HHS R13 NS082049NINDS NIH HHS R13NS082049
6 · The paper itself

Abstract

background and purposeThe Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke trial showed a trend for reduced all-cause mortality and positive secondary safety end point outcomes. We present further analyses of the mortality and severe disability data from the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke trial. MATERIALS AND

methodsThe Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke trial was a multicenter, randomized, controlled trial that evaluated the safety and effectiveness of the NeuroFlo catheter in patients with stroke. The current analysis was performed on the as-treated population. All-cause and stroke-related mortality rates at 90 days were compared between groups, and logistic regression models were fit to obtain ORs and 95% CIs for the treated versus not-treated groups. We categorized death-associated serious adverse events as neurologic versus non-neurologic events and performed multiple logistic regression analyses. We analyzed severe disability and mortality by outcomes of the mRS. Patient allocation was gathered by use of a poststudy survey.

resultsAll-cause mortality trended in favor of treated patients (11.5% versus 16.1%; P = .079) and stroke-related mortality was significantly reduced in treated patients (7.5% versus 14.2%; P = .009). Logistic regression analysis for freedom from stroke-related mortality favored treatment (OR, 2.41; 95% CI, 1.22, 4.77; P = .012). Treated patients had numerically fewer neurologic causes of stroke-related deaths (52.9% versus 73.0%; P = .214). Among the 90-day survivors, nominally fewer treated patients were severely disabled (mRS 5) (5.6% versus 7.5%; OR, 1.72; 95% CI, 0.72, 4.14; P = .223). Differences in allocation of care did not account for the reduced mortality rates.

conclusionsThere were consistent reductions in all-cause and stroke-related mortality in the NeuroFlo-treated patients. This reduction in mortality did not result in an increase in severe disability.

Indexed as

Disability EvaluationAdolescentAdultAgedAged, 80 and overBrain IschemiaFemaleHumansIncidenceInternationalityMaleMiddle AgedNervous System DiseasesRisk AssessmentStrokeSurvival Rate

Identifiers

PMID23828106
PMCPMC4156593
OpenAlexW2140016317

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.